Utility of the prostest to predict and monitor response to chemotherapy in metastatic Castration-Resistant prostate cancer: A prospective pilot study

Utility of the prostest to predict and monitor response to chemotherapy in metastatic Castration-Resistant prostate cancer: A prospective pilot study

Abstract Background Metastatic castration-resistant prostate cancer (mCRPC) treatment has advanced with therapies such as androgen receptor pathway inhibitors (ARPIs), taxane chemotherapies like docetaxel, and novel agents like 177Lu-PSMA. However, predicting patient responses and sequencing therapi...

Full description

Saved in:
Bibliographic Details
Main Authors: Kambiz Rahbar, Katrin Schlack, Martin Bögemann
Format: Article
Language:English
Published: BMC 2025-07-01
Series:BMC Cancer
Subjects:
PROSTest
Prostate cancer
Docetaxel
Online Access:https://doi.org/10.1186/s12885-025-14549-3
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items